The oncolytic adenovirus XVir-N-31 joins forces with CDK4/6 inhibition augmenting innate and adaptive antitumor immunity in Ewing sarcoma.

Sebastian Johannes Schober Caroline Schoening Jennifer Eck Charlotte Middendorf Julia Lutsch Pia Knoch Anna Josefine von Ofen Hendrik Gassmann Melanie Thiede Julia Hauer Andreas Kolk Klaus Mantwill Juergen E Gschwend Stefan E G Burdach Roman Nawroth Uwe Thiel Per Sonne Holm

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

The joint forces of the YB-1-driven oncolytic adenovirus XVir-N-31 and CDK4/6 inhibition induce therapeutically relevant local and systemic antitumor effects. Innate as well as adaptive immunity against EwS is boosted in this preclinical setting, pointing towards high therapeutic potential in the clinic.

Keyphrases

immune response
cell cycle
primary care
gene therapy
cell proliferation
bone marrow
mesenchymal stem cells